- Acquired by Genoptix, Dec 2017
- Raised $6M funding round led by Kadima High Tech, Sep 2005
About
Rosetta Genomics develops and commercializes a range of microRNA-based and other molecular diagnostics. The companys integrative research platform, combining bioinformatics and laboratory processes, has led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta Genomics is advancing and developing multiple diagnostic programs for cancer and various other indications to enable accurate diagnosis and prognosis and to improve patient care management worldwide. The RosettaGX platform of tests uses blended technology platforms (e.g. microRNA, FISH, and next-generation sequencing) along with proprietary scientific approaches for each tumor type in its offering. It chooses the most clinically informative and relevant testing based on an ongoing and thorough review of scientific literature and an internal medical review process.
Funding history · 1 round · $6.0M total
Q&A
- What is Rosetta Genomics' primary focus?
- Rosetta Genomics develops and commercializes microRNA-based and other molecular diagnostics, primarily for cancer and various other indications to improve patient care.
- When was Rosetta Genomics founded?
- Rosetta Genomics was founded in March 2000.
- What is the current status of Rosetta Genomics?
- Rosetta Genomics was acquired by Genoptix in December 2017 and is currently inactive.
- How much funding has Rosetta Genomics raised in total?
- Rosetta Genomics has raised a total of $6,000,000.
- When was Rosetta Genomics' last funding round and who were the lead investors?
- Rosetta Genomics' last funding round was in September 2005, with Kadima High Tech as a lead investor.
- What is the employee count for Rosetta Genomics?
- Rosetta Genomics has an employee count in the 51-200 range.
- Where is Rosetta Genomics headquartered?
- Rosetta Genomics is headquartered in Rehovot, Center District, Israel.
- What technology platforms does Rosetta Genomics utilize in its RosettaGX tests?
- The RosettaGX platform of tests uses blended technology platforms including microRNA, FISH, and next-generation sequencing.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
Identifiers & details
| Founded | 2000-3 |
|---|---|
| Employees (exact) | 74 |
| Offices | Philadelphia; Lake Forest |
| Status reason | Acquired (Inactive) by Genoptix on Dec 2017 - closed due to acquisition |
| Wikidata QID | Q7368685 |
Acquisitions & public offerings
Acquired by Genoptix 2017-12
Radar intelligence
Patents
| EPO | 74 |
|---|
Wikidata
| QID | Q7368685 |
|---|